Navigation Links
Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
Date:12/13/2012

hase 3 registrational study of ARIKACE (CLEAR-108) in Europe and Canada has completed enrollment, and the Company expects top-line clinical results in mid-2013.  Insmed's U.S. phase 2 clinical trial in NTM (TARGET-NTM) is well under way with clinical results expected in late 2013.  The Company is currently preparing for regulatory filings and for commercialization, if and when regulatory approvals are obtained. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Words, and variations of words, such as "intend", "expect", "will", "anticipate", "believe", "continue", "propose" and similar expressions are intended to identify forward-looking statements. Investors are cautioned that such statements in this release, including statements relating to the status, results and timing of results of pre-clinical studies and clinical trials and pre-clinical and clinical data and the anticipated benefits of Insmed's products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, without limitation, failure or delay of U.S. Food and Drug Administration and other regulatory reviews and approvals, competitive developments affecting our product development, delays in product development or clinical trials, patent disputes involving currently developing products, unexpected regulatory actions, delays or requests, the failure of future clinical trials, inability to successfully develop our product candidates or receive necessary regulatory approvals, inability to make product candidates commercially successful, changes in anticipated expenses, and other risks and challenges detailed in our filings
'/>"/>

SOURCE Insmed Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Insmed Incorporated Provides Corporate Update
2. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
3. Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
4. Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
5. Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... LAKE FOREST, California , 17 de ... BB: CYRX) ("la compañía"), principal proveedor mundial ... industria de las ciencias de la vida, ... una compañía de logística global con sede ... a su base de clientes Europa en ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/17/2014)... The Alliance for Clinical ... non-profit collaborative building a global system to enhance ... announced Phase 3 of its Site Accreditation and ... H. Kalali, Vice-President, Global Head, Neuroscience Center of ... and Quality Integration (CQI) Consulting will lead the ...
(Date:9/16/2014)... strap that can harvest energy from jaw movements has ... , It is hoped that the device can generate ... number of small-scale implantable or wearable electronic devices, such ... communication devices. , The first results of the device,s ... Publishing,s journal Smart Materials and Structures . , ...
Breaking Biology Technology:Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4'Smart material' chin strap harvests energy from chewing 2
... 2011 Landauer, Inc. (NYSE: LDR ... monitoring and the leading domestic provider of outsourced medical physics ... quarter ended March 31, 2011.   Fiscal 2011 ... to $32.3 million on contribution from Medical Physics segment and ...
... N.J., May 3, 2011 BioNeutral Group, Inc. ... today announced that it has signed on to ... disinfectant technology to the infection control professionals attending ... in Infection Control and Epidemiology) ( www.apic.org ). ...
... Inc. (Nasdaq: VVUS ), a biopharmaceutical company dedicated to ... financial results for the first quarter ended March 31, 2011. ... 2011, VIVUS reported a net loss of $9.9 million or $0.12 ... or $0.23 per share for the first quarter of 2010. The ...
Cached Biology Technology:Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 12BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 2BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 3BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 4VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5
(Date:9/16/2014)... consumers to make ethical choices such as buying clothing ... on fair-trade coffee, and bringing their own bags when ... the Journal of Consumer Research , ethical consumption ... their emotions about unethical practices into action. , "Advocates ... environmental and human costs of the products they choose, ...
(Date:9/16/2014)...  Valencell, Inc., a leader in performance biometric data ... "Showcase Companies" representing North Carolina,s ... Venture Conference on September 16-17 th at the ... Raleigh, North Carolina . Valencell,s President Dr. ... the "Digital Health Spotlight Sector" on how the Company,s ...
(Date:9/16/2014)... of wild foods, autumn harks a season of bounty. ... luring intrepid collectors to woodlands in search of elusive ... in the allure of the treasure hunt, and their ... existence. But are the mushrooms which you are eating ... diverse yet vastly underdocumented although some estimates range ...
Breaking Biology News(10 mins):Why are consumers willing to spend more money on ethical products? 2Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 3
... the University of Iowa Carver College of Medicine have ... a defective protein, which is the most common cause ... inherited disease caused by mutations in a gene that ... and cellular location, this protein, cystic fibrosis transmembrane conductance ...
... diamond-back moth. It lays its eggs on the cabbage plants ... However, Morten Emil Mldrup from the University of Copenhagen has ... his spectacular research results at a public PhD defense on ... cheat the diamond-back moths to lay their eggs on tobacco ...
... summarize research papers that have been recently published in ... (JGR-D), Journal of Geophysical Research-Space Physics (JGR-A), ... Journal of Geophysical Research-Oceans (JGR-C). In this ... river catchments, 2. Atmospheric CO2 drove climate change during ...
Cached Biology News:Gene network restores CF protein function 2Gene technology helps deceive greedy pest insects 2AGU journal highlights -- 31 July 2012 2AGU journal highlights -- 31 July 2012 3AGU journal highlights -- 31 July 2012 4AGU journal highlights -- 31 July 2012 5AGU journal highlights -- 31 July 2012 6AGU journal highlights -- 31 July 2012 7AGU journal highlights -- 31 July 2012 8AGU journal highlights -- 31 July 2012 9AGU journal highlights -- 31 July 2012 10
Dedicated 29.5" X 18" platforms for Stackable shakers. These platforms are optimized for a particular flask clip size and are sold with a full load of flask clips....
Request Info...
... BioPrime Plus Array CGH Genomic Labeling Systems ... reproducible labeling of genomic DNA samples for ... both indirect and direct labeling formats, the ... provide a flexible solution to your genomic ...
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
Biology Products: